Introduction To complement islet transplantation for type1 diabetic patients, cell-based
therapy using pluripotent stem cells such as ES cells and iPS cells is promising. Many …

Type 1 and 2 diabetes are characterized by a deficiency in β-cell mass, which cannot be
reversed with existing therapeutic strategies. Therefore, restoration of the endogenous …

Background Transplantation of islets of Langerhans is regarded as a promising therapy for
type 1 diabetes. A large number of β-cells are required for the treatment of human type 1 …

Type 1 diabetes (T1D) is caused by autoimmune disease that leads to the destruction of
pancreatic β-cells. Transplantation of cadaveric pancreatic organs or pancreatic islets can …

Human induced pluripotent stem (iPS) cells obtained from patients are expected to be a
useful source for cell transplantation therapy, because many patients (including those with …

Human pluripotent stem cells represent a potentially unlimited source of functional
pancreatic endocrine lineage cells. Here we report a highly efficient approach to induce …

Objectives: Islet transplantation is hampered by the shortage of donor tissues. Our objective
was to generate islet-like cell clusters (ICCs) from cultures of non-islet pancreatic cells …

Introduction Although immunosuppressants are required for current islet transplantation for
type 1 diabetic patients, many papers have already reported encapsulation devices for islets …

Cellular replacement therapy holds promise for the treatment of diabetes mellitus but donor
tissue is severely limited. Therefore, we investigated whether insulin-secreting cells could be …

Pancreatic islets of Langerhans exhibit an architecture and cellular organization ideal for
rapid, yet finely controlled, responses to changes in blood glucose levels. In type I, insulin …